适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 yearsCTIS2023-508447-52-00Bayer AG20
进行中（未招募）
1 期
A study to compare how much of the study treatment finerenone gets into the blood when the same amount is taken in one and in two tablets in healthy male participantsCTIS2022-502385-24-00Bayer AG60
进行中（未招募）
1 期
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.MedDRA version: 20.1Level: LLTClassification code: 10054109Term: Non-proliferative diabetic retinopathy Class: 10015919MedDRA version: 23.1Level: PTClassification code: 10064848Term: Chronic kidney disease Class: 100000004857Chronic kidney diseaseCTIS2024-510856-11-00Bayer AG15
进行中（未招募）
1 期
A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participantsCTIS2023-508905-26-00Bayer AG40
招募中
1 期
A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 compared with placebo.Sepsis associated disseminated intravascular coagulationMedDRA version: 22.0Level: PTClassification code: 10013442Term: Disseminated intravascular coagulation Class: 100000004851MedDRA version: 20.0Level: PTClassification code: 10040047Term: Sepsis Class: 100000004862CTIS2022-502866-25-00Bayer AG86